Chloroquine and Coartem for Treatment of Symptomatic Children With Plasmodium Falciparum in Guinea Bissau
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This study will evaluate the efficacy of treatment with artemether-lumefantrine as compared to chloroquine in the dose of 50 mg/kg for treatment of malaria in children in Guinea-Bissau. The genetic basis of the parasites for developing resistance will be examined. Children coming to one of the Health Centres with symptoms of malaria and a positive malaria test will be included. The children will be followed weekly until day 70. In case of reappearance of parasites the child will be re-treated with the opposite study drug.
| Condition | Intervention | Phase |
|---|---|---|
|
Malaria, Falciparum |
Drug: Chloroquine Drug: Artemether-lumefantrine (Coartem) |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Chloroquine and Coartem for Treatment of Symptomatic Children With Plasmodium Falciparum in Guinea Bissau. |
- Parasite reappearance rate, [ Time Frame: 70 days ] [ Designated as safety issue: No ]
- genetic markers of resistance [ Time Frame: 70 days ] [ Designated as safety issue: No ]
- recrudescence and re-infection rates [ Time Frame: 70 days ] [ Designated as safety issue: No ]
- Hospitalisation during follow-up [ Time Frame: 70 days ] [ Designated as safety issue: No ]
- Haemoglobin changes [ Time Frame: 70 days ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 300 |
| Study Start Date: | December 2006 |
| Study Completion Date: | November 2008 |
| Primary Completion Date: | November 2008 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: 1 Coartem
Treatment of documented malaria in children following the dosages recommended by the manufacturer.
|
Drug: Chloroquine
Chloroquine tablets gives as 50 mg/kg divided into 6 doses giver twice a day for 3 days.
Drug: Artemether-lumefantrine (Coartem)
Will be dosed according to the recommendations of WHO. Will be given at time: 0 h, 8 h, 24 h, 36 h,48 h and 60 h. The dosage will be according to bodyweight of the child as follows: 5-14 kg: 1 tablet, 15-24 kg: 2 tablets, 25-34 kg: 3 tablets, < 34 kg: 4 tablets.
Other Name: Brand name: Coartem.
|
|
Active Comparator: 2 Chloroquine
The antimalarial actually used in Guinea-Bissau is the dosage of 50 mg/kg given twice a day for 3 days.
|
Drug: Chloroquine
Chloroquine tablets gives as 50 mg/kg divided into 6 doses giver twice a day for 3 days.
Drug: Artemether-lumefantrine (Coartem)
Will be dosed according to the recommendations of WHO. Will be given at time: 0 h, 8 h, 24 h, 36 h,48 h and 60 h. The dosage will be according to bodyweight of the child as follows: 5-14 kg: 1 tablet, 15-24 kg: 2 tablets, 25-34 kg: 3 tablets, < 34 kg: 4 tablets.
Other Name: Brand name: Coartem.
|
Detailed Description:
This study compares treatment of uncomplicated malaria in children in Guinea-Bissau with artemether-lumefantrine (Coartem) with that of treatment with chloroquine 50 mg/kg. Furthermore, the genetic basis of anti-malarial resistance in Guinea-Bissau will be studied by analyzing specific single nucleotide polymorphisms in pfcrt and pfmdr1 in blood samples from this in vivo trial. We also intend to study whether the recent report that chloroquine sensitive parasites are selected at recrudescence after Coartem is confirmed in Bissau.
Following consent to participate, children visiting one of the Health Centres in the study area with mono-infection with Plasmodium falciparum are by block-randomization allocated to one of the treatment groups. The treatment is given supervised by one of the health workers and malaria film taken on day 2 and 3. The children are visited and malaria films obtained once weekly until day 70. On day seven, 100 microliter of capillary blood are drawn for analyses of analyses of drug concentrations in whole blood. On inclusion and whenever a child has recurrent parasitaemia, a filter-paper blood-sample is collected for later PCR analysis. On the day of inclusion, on day 42 and on day 70 the haemoglobin level is measured.
If parasites reappear in 50% or more of at least 40 children in one of the treatment groups this treatment arm should be terminated. During the study parents are recommended to bring the child to the health centre in case of any illness. Participating children will be examined and treated free of charge. The opposite study drug will be used for re-treatment of children in case of recrudescence, and the child will be followed as previously planned.
The results from this study could be used for the planning of the recommendations for treatment of malaria in Guinea-Bissau. It will provide the National Malaria Programme with information of the efficacy of Coartem before it is implemented.
Eligibility| Ages Eligible for Study: | 6 Months to 15 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Children presenting at one of the health centres in the study area
- Symptoms suggestive of malaria
- At least 20 P.falciparum parasites per 200 leucocytes
- Living in the study area (to enable follow-up)
Exclusion Criteria:
- Danger signs
- By the responsible doctor evaluated to need to be transferred to the national hospital as an in-patient
- Previous idiosyncratic reactions to any of the study drugs
Contacts and Locations More Information
No publications provided by Bandim Health Project
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Dr. Poul-Erik Kofoed, Bandim Heath Project |
| ClinicalTrials.gov Identifier: | NCT00426439 History of Changes |
| Other Study ID Numbers: | PSB-2006-Coartem |
| Study First Received: | January 23, 2007 |
| Last Updated: | January 2, 2011 |
| Health Authority: | Guinea-Bissau: Ministry of Health |
Keywords provided by Bandim Health Project:
|
malaria Plasmodium falciparum children Guinea-Bissau |
artemether lumefantrine chloroquine Coartem |
Additional relevant MeSH terms:
|
Malaria Malaria, Falciparum Protozoan Infections Parasitic Diseases Chloroquine Chloroquine diphosphate Artemether Lumefantrine Artemether-lumefantrine combination Artemisinins Amebicides Antiprotozoal Agents Antiparasitic Agents Anti-Infective Agents Therapeutic Uses |
Pharmacologic Actions Antimalarials Antirheumatic Agents Anti-Inflammatory Agents, Non-Steroidal Analgesics, Non-Narcotic Analgesics Sensory System Agents Peripheral Nervous System Agents Physiological Effects of Drugs Anti-Inflammatory Agents Filaricides Antinematodal Agents Anthelmintics Central Nervous System Agents Antifungal Agents |
ClinicalTrials.gov processed this record on May 16, 2013